Citations

Showing 10 of 108036 citations.

Understanding Family Interaction Patterns in Families With Alzheimer’s Disease
Schaber, Patricia, Blair, Kate, Jost, Ellen, Schaffer, Molly, Thurner, Emily, Blair, Kate

Mayo Clinic

OTJR: Occupational Therapy Journal of Research | October 8, 2015 | Volume: 36 | Issue: 1 | Pages: 25-33

10.1177/1539449215610566 | PMID 27504690 Get It

This qualitative study explores the dynamic changes that occur in family interaction patterns when Alzheimer’s disease is present. Semi-structured interviews were conducted with 15 participants who have a family member with the disease. Using modified analytic induction, guided by the dimensions of the Family Fundamental Interpersonal Relations Orientation (FIRO) Model, participants shared how Alzheimer’s disease affected family structure, control dynamics, and intimacy among family members. Findings demonstrate that (a) families reorganize and restructure based on geographic proximity and shifting roles, act out of filial responsibility, and strive to preserve shared meanings and rituals; (b) decision making increases around care of the person with Alzheimer’s disease and shifts to the primary caregiver or other family members based on their abilities; and (c) expressions of intimacy intensify while personality is preserved in the person with the disease. The Family FIRO model can inform practitioners using family-centered care with families with Alzheimer’s disease.
How to use D-dimer in acute cardiovascular care
Mair, Johannes , Siegbahn, Agneta , Huber, Kurt , Jaffe, Allan S. , Thygesen, Kristian , Möckel, Martin , Mueller, Christian, Giannitsis, Evangelos , Christersson, Christina , Jaffe, Allan S. , Peacock, William Frank , Plebani, Mario , Lindahl, Bertil , Huber, Kurt , Mockel, Martin

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | October 8, 2015 | Volume: 6 | Issue: 1 | Pages: 69-80

10.1177/2048872615610870 | PMID 26450781 Get It

Casein Kinase II Phosphorylates IκBα at S-283, S-289, S-293, and T-291 and Is Required for Its Degradation
McElhinny, J A, Trushin, Sergey A., Bren, Gary D., Chester, Nicholas, Payá, Carlos V.

Mayo Clinic

Molecular and Cellular Biology | October 8, 2015 | Volume: 16 | Issue: 3 | Pages: 899-906

10.1128/mcb.16.3.899 | PMID 8622692 Get It

Interleukin-2 Triggers a Novel Phosphatidylinositol 3-Kinase-Dependent MEK Activation Pathway
Karnitz, Larry M., Burns, L A, Sutor, Shari L., Blenis, John , Abraham, Robert T.

Mayo Clinic

Molecular and Cellular Biology | October 8, 2015 | Volume: 15 | Issue: 6 | Pages: 3049-3057

10.1128/mcb.15.6.3049 | PMID 7760801 Get It

Meeting the Tobacco Cessation Coverage Requirement of the Patient Protection and Affordable Care Act: State Smoking Cessation Quitlines and Cost Sharing
Bailey, Linda A., Leischow, Scott J. , Lemaire, Robin H, Bailey, Linda, Lemaire, Robin Hargroder

Mayo Clinic

American Journal of Public Health | October 8, 2015 | Volume: 105 | Issue: S5 | Pages: S699-S705

10.2105/ajph.2015.302869 | PMID 26447918 Get It

Objectives. We explored whether various key stakeholders considered cost sharing with state telephone-based tobacco cessation quitlines, because including tobacco cessation services as part of the required essential health benefits is a new requirement of the Patient Protection and Affordable Care Act (ACA). Methods. We analyzed qualitative data collected from interviews conducted in April and May of 2014 with representatives of state health departments, quitline service providers, health plans, and insurance brokers in 4 US states. Results. State health departments varied in the strategies they considered the role their state quitline would play in meeting the ACA requirements. Health plans and insurance brokers referred to state quitlines because they were perceived as effective and free, but in 3 of the 4 states, the private stakeholder groups did not consider cost sharing. Conclusions. If state health departments are going to initiate cost-sharing agreements with private insurance providers, then they will need to engage a broad array of stakeholders and will need to overcome the perception that state quitline services are free.
Patent foramen ovale in liver transplant recipients does not negatively impact short‐term outcomes
Werlang, Monia E., Palmer, William C. , Boyd, Evelyn , Cangemi, David J. , Harnois, Denise M. , Taner, Cemal Burcin, Stancampiano, Fernando F. , Boyd, Evelyn A, Taner, Cemal B, Stancampiano, Fernando F

Mayo Clinic

Clinical Transplantation | October 8, 2015 | Volume: 30 | Issue: 1 | Pages: 26-32

10.1111/ctr.12643 | PMID 26448343 Get It

AbstractAimPatent foramen ovale (PFO) is a common atrial septal defect that is largely asymptomatic and often undiagnosed. The impact of aPFOin patients undergoing liver transplantation (LT) is unknown.ObjectiveAssess the impact ofPFOand physiologic intrapulmonary shunt (IPS) on the perioperative outcomes of patients who underwentLT.MethodsWe performed a retrospective, intention‐to‐treat analysis of patients withPFOand controls withoutPFOwho underwentLTat Mayo Clinic in Florida between 2008 and 2013. Patients with physiologicIPSwere also analyzed. The cohorts were compared for baseline characteristics, length of stay in the intensive care unit (ICU), postoperative oxygen requirements, 30‐d cerebrovascular accidents, and mortality.ResultsOf the 935 patients who underwentLT, 10.4% had provenPFOby pre‐LTechocardiogram. Control patients (n = 101) were statistically older thanPFOandIPS(n = 56) patients, but similar in sex,BMI, Model for End‐stage Liver Disease score, American Society of Anesthesiologist score, and left ventricular ejection fraction.PFOandIPSpatients had similar length of stay in theICU, mechanical ventilation times, post‐LToxygen requirements, and 30‐d mortality compared to controls. Subgroup analysis showed similar outcomes for largePFOandIPSpatients to controls.ConclusionsThe presence ofPFOdid not have a negative impact on perioperativeLToutcomes.
ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA‐matched peripheral blood hematopoietic cell transplantation after reduced‐intensity conditioning
Litzow, Mark R. , Gastineau, Dennis A., Jacob, Eapen, Damlaj, Moussab , Hashmi, Shahrukh K. , Al‐Kali, Aref , Patnaik, Mrinal M. , Hogan, William, Gastineau, Dennis, Hashmi, Shahrukh, Hefazi, Mehrdad , Hogan, William J. , Gastineau, Dennis A.

Mayo Clinic

Transfusion | October 8, 2015 | Volume: 56 | Issue: 2 | Pages: 518-527

10.1111/trf.13353 | PMID 26446051 Get It

BACKGROUNDABO incompatibility is not a contraindication to hematopoietic cell transplantation (HCT), but it has been associated with additional risks including delayed engraftment, pure red cell aplasia (PRCA), and higher transfusion needs. Data on these events and on patient survival after reduced‐intensity conditioning (RIC) HCT are limited.STUDY DESIGN AND METHODSA total of 127 consecutive patients, 86 with acute myeloid leukemia and 41 with myelodysplastic syndromes, who underwent HLA‐matched peripheral blood RIC allogenic HCT between 2005 and 2014 were retrospectively analyzed.RESULTSEighty ABO‐compatible, 26 major/bidirectional, and 21 minor‐ABO‐mismatch HCT were identified. Compared to the ABO‐compatible group, major/bidirectional mismatches had increased red blood cell (RBC) transfusion requirement during the first 100 days (p = 0.009), delayed RBC and PLT engraftment (p = 0.0011 and p = 0.005, respectively), and higher incidence of grade II to IV acute graft‐versus‐host disease (aGVHD; p = 0.037). In multivariable analysis, major/bidirectional mismatches had significantly higher non‐relapse mortality (NRM) and inferior disease‐free survival (DFS) and overall survival (OS) compared with ABO‐compatible patients (p = 0.01, p = 0.04, and p = 0.035, respectively). Minor ABO mismatch had no impact on survival (p = 0.99). Four (15%) of 26 major/bidirectional mismatches developed PRCA. There was a significant association between fludarabine plus busulfan conditioning and PRCA (p = 0.0046).CONCLUSIONMajor/bidirectional ABO mismatch is associated with higher NRM and shortened DFS and OS in the setting of RIC HCT. Increased transfusion need, delayed RBC and platelet engraftment, PRCA, and increased severity of aGVHD are additional complications contributing to the morbidity.
A Structurally Unresolved Head Segment of Defined Length Favors Proper Measles Virus Hemagglutinin Tetramerization and Efficient Membrane Fusion Triggering
Navaratnarajah, Chanakha K. , Rosemarie, Quincy , Cattaneo, Roberto

Mayo Clinic

Journal of Virology | October 8, 2015 | Volume: 90 | Issue: 1 | Pages: 68-75

10.1128/jvi.02253-15 | PMID 26446605 Get It

ABSTRACT Paramyxoviruses include several insidious and ubiquitous pathogens of humans and animals, with measles virus (MeV) being a prominent one. The MeV membrane fusion apparatus consists of a receptor binding protein (hemagglutinin [H]) tetramer and a fusion (F) protein trimer. Four globular MeV H heads are connected to a tetrameric stalk through flexible linkers. We sought here to characterize the function of a 17-residue H-head segment proximal to the stalk that was unresolved in all five MeV H-head crystal or cocrystal structures. In particular, we assessed whether its primary sequence and length are critical for proper protein oligomerization and intracellular transport or for membrane fusion triggering. Extensive alanine substitutions had no effect on fusion triggering, suggesting that sequence identity is not critical for this function. Excessive shortening of this segment reduced or completely abrogated fusion trigger function, while length compensation restored it. We then characterized the mechanism of function loss. Mutated H proteins were efficiently transported to the cell surface, but certain alterations enhancing linker flexibility resulted in accumulation of high-molecular-weight H oligomers. Some oligomers had reduced fusion trigger capacity, while others retained this function. Thus, length and rigidity of the unresolved head segment favor proper H tetramerization and counteract interactions between subunits from different tetramers. The structurally unresolved H-head segment, together with the top of the stalk, may act as a leash to provide the right degree of freedom for the heads of individual tetramers to adopt a triggering-permissive conformation while avoiding improper contacts with heads of neighboring tetramers. IMPORTANCE Understanding the molecular mechanism of membrane fusion triggering may allow development of new antiviral strategies. The fusion apparatus of paramyxoviruses consists of a receptor binding tetramer and a fusion protein trimer. Structural analyses of the receptor binding hemagglutinin-neuraminidases of certain paramyxoviruses suggest that fusion triggering is preceded by relocation of its head domains, facilitated by flexible linkers. Having noted a structurally unresolved 17-residue segment linking the globular heads to the tetrameric stalk of the measles virus hemagglutinin (H), we asked whether and how it may facilitate membrane fusion triggering. We conclude that, together with the top of the stalk, the flexible linker keeps H heads on a leash long enough to adopt a triggering-permissive conformation but short enough to limit roaming and improper contacts with heads of neighboring tetramers. All morbillivirus H-protein heads appear to be connected to their stalks through a “leash,” suggesting a conserved triggering mechanism.
Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome?
Godoy, Daniel Agustín , Rabinstein, Alejandro A.

Mayo Clinic

Arquivos de Neuro-Psiquiatria | October 8, 2015 | Volume: 73 | Issue: 10 | Pages: 848-851

10.1590/0004-282x20150136 | PMID 26465402 Get It

Objective In certain situations, severe forms of Guillain-Barré syndrome (GBS) show no response or continue to deteriorate after intravenous immunoglobulin (IVIg) infusion. It is unclear what the best treatment option would be in these circumstances.Method This is a case report on patients with severe axonal GBS in whom a second cycle of IVIg was used.Results Three patients on mechanical ventilation who presented axonal variants of GBS, with autonomic dysfunction, bulbar impairment and Erasmus score > 6, showed no improvement after IVIg infusion of 400 mg/kg/d for 5 days. After 6 weeks, we started a second cycle of IVIg using the same doses and regimen as in the previous one. On average, 5 days after the second infusion, all the patients were weaned off mechanical ventilation and showed resolution of their blood pressure and heart rate fluctuations.Conclusions A second cycle of IVIg may be an option for treating severe forms of GBS.
Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer
Hurley, Paula J. , Sundi, Debasish , Shinder, Brian , Hughes, Robert M. , Miller, Rebecca M., Benzon, Benjamin , Faraj, Sheila F., Netto, George J. , Vergara, Ismael A. , Erho, Nicholas , Karnes, R. Jeffrey , Yan, Guifang, Ewing, Charles M., Isaacs, Sarah D., Berman, David M. , Rider, Jennifer R. , Jordahl, Kristina M. , Mucci, Lorelei A. , Huang, Jessie , An, Steven S. , Isaacs, William B. , Marchionni, Luigi , Ross, Ashley E. , Schaeffer, Edward M. , Simons, Brian W. , Davicioni, Elai , Park, Ben Ho

Mayo Clinic

Clinical Cancer Research | October 7, 2015 | Volume: 22 | Issue: 2 | Pages: 448-458

10.1158/1078-0432.ccr-15-0256 | PMID 26446945 Get It

Abstract Purpose: Prostate cancers incite tremendous morbidity upon metastatic growth. We previously identified Asporin (ASPN) as a potential mediator of metastatic progression found within the tumor microenvironment. ASPN contains an aspartic acid (D)-repeat domain and germline polymorphisms in D-repeat-length have been associated with degenerative diseases. Associations of germline ASPN D polymorphisms with risk of prostate cancer progression to metastatic disease have not been assessed. Experimental Design: Germline ASPN D-repeat-length was retrospectively analyzed in 1,600 men who underwent radical prostatectomy for clinically localized prostate cancer and in 548 noncancer controls. Multivariable Cox proportional hazards models were used to test the associations of ASPN variations with risk of subsequent oncologic outcomes, including metastasis. Orthotopic xenografts were used to establish allele- and stroma-specific roles for ASPN D variants in metastatic prostate cancer. Results: Variation at the ASPN D locus was differentially associated with poorer oncologic outcomes. ASPN D14 [HR, 1.72; 95% confidence interval (CI), 1.05–2.81, P = 0.032] and heterozygosity for ASPN D13/14 (HR, 1.86; 95% CI, 1.03–3.35, P = 0.040) were significantly associated with metastatic recurrence, while homozygosity for the ASPN D13 variant was significantly associated with a reduced risk of metastatic recurrence (HR, 0.44; 95% CI, 0.21–0.94, P = 0.035) in multivariable analyses. Orthotopic xenografts established biologic roles for ASPN D14 and ASPN D13 variants in metastatic prostate cancer progression that were consistent with patient-based data. Conclusions: We observed associations between ASPN D variants and oncologic outcomes, including metastasis. Our data suggest that ASPN expressed in the tumor microenvironment is a heritable modulator of metastatic progression. Clin Cancer Res; 22(2); 448–58. ©2015 AACR.